Orca Biosystems, Inc.   Report issue

For profit Phase 1
Founded: Menlo Park CA United States (2016)

Organization Overview

First Clinical Trial
2019
NCT04013685
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Orca Biosystems, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, Lymphoid (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Preleukemia (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 9